Literature DB >> 18489523

Differential expression of angiopoietin-2 and vascular endothelial growth factor in androgen-independent prostate cancer models.

Tajana Tesan1, Heléne Gustavsson, Karin Welén, Jan-Erik Damber.   

Abstract

OBJECTIVE: To investigate the relationship between microvessel density (MVD), blood vessel morphology and the expression of angiopoietin (Ang)-1, Ang-2, tyrosine kinase with immunoglobulin and epidermal growth factor homology domains (Tie)-2, and vascular endothelial growth factor (VEGF) in androgen-dependent (AD) and androgen-independent (AI) prostate cancer models, to gain insight into the regulation of angiogenesis at different stages of prostate cancer.
MATERIALS AND METHODS: MVD and blood vessel morphology were evaluated by CD34 immunohistochemical staining. The mRNA and protein secretion of the Angs, Tie-2 and VEGF were measured by real-time polymerase chain reaction and enzyme-linked immunosorbent assays, respectively, in LNCaP (AD) and LNCaP-19, C4-2, C4-2B4 and PC-3 (AI) prostate cancer xenografts in mice.
RESULTS: LNCaP, C4-2 and C4-2B4 xenografts had high expression of Ang-2 and VEGF, similar MVD and blood vessel morphology. However, the most angiogenic cell line LNCaP-19 expressed low levels of both factors and had different vessel morphology. PC-3 xenografts had a similar MVD to LNCaP, C4-2 and C4-2B4, but the Ang-2 and VEGF expression as well as the vessel morphology were similar to LNCaP-19.
CONCLUSION: The differences in MVD, blood vessel morphology and the expression of Ang-2 and VEGF show that prostate cancer cells display angiogenic heterogeneity, which indicates different roles of these factors in the regulation of angiogenesis in different stages of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489523     DOI: 10.1111/j.1464-410X.2008.07768.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  3 in total

1.  Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.

Authors:  Colm Morrissey; Alex Dowell; Theodore D Koreckij; Holly Nguyen; Bryce Lakely; William C Fanslow; Lawrence D True; Eva Corey; Robert L Vessella
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

2.  Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells.

Authors:  Mikhail G Dozmorov; Robert E Hurst; Daniel J Culkin; Bradley P Kropp; Mark Barton Frank; Jeanette Osban; Trevor M Penning; Hsueh-Kung Lin
Journal:  Prostate       Date:  2009-07-01       Impact factor: 4.104

Review 3.  Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.

Authors:  Hisham F Bahmad; Mohammad Jalloul; Joseph Azar; Maya M Moubarak; Tamara Abdul Samad; Deborah Mukherji; Mohamed Al-Sayegh; Wassim Abou-Kheir
Journal:  Front Genet       Date:  2021-03-26       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.